Drug resistance marker | Number of mutations | Mutation haplotype | DAPPQ n = 55 | AS/SP n = 49 | Total (n 104) n (%) |
---|---|---|---|---|---|
dhfr | None | Wild type NCSI | 3 (5.45%) | 0 (0%) | 3 (2.9%) |
Double | ICNI | 40 (72.7%) | 32 (65.3%) | 72 (69.2%) | |
NRNI | 1 (1.8%) | 6 (12.2%) | 7 (6.7%) | ||
Triple | IRNI | 11 (20%) | 11 (22.4%) | 22 (21.1%) | |
dhps | None | Wild type SAKAA | 11(20%) | 3 (6.1) | 14 (13.5%) |
Single | AAKAA | 4 (7.3%) | 0 (0%) | 4 (3.8%) | |
SGKAA | 4 (7.3%) | 3 (6.1) | 7 (6.7%) | ||
Double | SGEAA | 15 (27.3) | 17 (34.7%) | 32 (30.7%) | |
Triple | SGEGA | 21 (38.1) | 24 (48.9%) | 45 (43.2%) | |
AGEAA | 0 (0%) | 1 (2%) | 1 (0.96%) | ||
SGEAT | 0 (0%) | 1 (2%) | 1 (0.96%) | ||
dhfr + dhps | None | Wild type NCSI + SAKAA | 1 (1.8%) | 0 (0%) | 1 (0.96%) |
Single | NCSI + AAKAA | 2 (3.6%) | 0 (0%) | 2 (1.9%) | |
Double | ICNI +SAKAA | 8 (14.5%) | 3 (6.1%) | 11 (10.6%) | |
Triple | IRNI +SAKAA | 2 (3.6%) | 0 (0%) | 2 (1.9%) | |
ICNI + AAKAA | 3 (5.45%) | 0 (0%) | 3 (2.9%) | ||
ICNI + SGKAA | 0 (0%) | 2 (4%) | 2 (1.9%) | ||
NRNI + SGKAA | 1 (1.8%) | 1 (2%) | 2 (1.9%) | ||
Quadruple | IRNI + SGKAA | 2 (3.6%) | 0 (0%) | 2 (1.9%) | |
ICNI + SGEAA | 14 (25.5%) | 9 (18.4%) | 23 (22.1%) | ||
NRNI + SGEAA | 0 (0%) | 1 (2%) | 1 (0.96%) | ||
Quintuple | IRNI + SGEAA | 1 (1.8%) | 7 (14.3%) | 8 (7.7%) | |
ICNI + AGEAA | 0 (0%) | 1 (2%) | 1 (0.96%) | ||
ICNI + SGEGA | 15 (27.3) | 16 (32.6%) | 31 (29.8%) | ||
ICNI + SGEAT | 0 (0%) | 1 (2%) | 1 (0.96%) | ||
NRNI I + SGEGA | 0 (0%) | 4 (8.1%) | 4 (3.8%) | ||
Hextuple | IRNI + SGEGA | 6 (10.9%) | 4 (8.1%) | 10 (9.6%) |